Market Update Economic Events Directors Deals Commodities Prices News Market Movers

Motif Bio presents skin treatment study data at Lisbon conference

Wednesday, 5th September 2018
Antibiotic developer Motif Bio said it was presenting data on the skin treatment iclaprim at an industry conference in Lisbon.

The safety study data was being presented at the European Society of Clinical Microbiology and Infectious Diseases/American Society for Microbiology Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, being held September 4-7.

'We have shown comprehensive data indicating that iclaprim has potent activity against a wide variety of Gram-positive bacteria, including MRSA, that cause severe skin infections,' chief medical officer David Huang said.

'With its targeted Gram-positive spectrum of activity, low propensity for resistance development, favourable tolerability profile and efficacy results, we think that, if approved, iclaprim could be an important new treatment option for patients with ABSSSI.'

Story provided by

Related Shares: Motif Bio

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.